Lilly Files Zyprexa Injection In Japan
This article was originally published in PharmAsia News
Executive Summary
Kobe-based Eli Lilly &Co. Japan has submitted application for Zyprexa (olanzapin) intra-muscle rapid acting injection for schizophrenia in Japan